10-Q: Cyclerion Therapeutics Shifts Focus to Depression, Raises Capital

Cyclerion Therapeutics reports reduced net losses and increased revenue, secures a new license for treatment-resistant depression, but faces substantial doubt about its ability to continue as a going concern.

Summary

• Net loss for the nine months ended September 30, 2025, significantly decreased to $2.7 million from $3.6 million in the prior year.
• Total revenues for the nine months ended September 30, 2025, surged to $1.049 million, up from $0.194 million in the same period last year.
• Cash and cash equivalents increased to $4.568 million as of September 30, 2025, from $3.232 million at December 31, 2024.
• The company secured an exclusive worldwide license from MIT in September 2025 for intellectual property related to an individualized therapy for treatment-resistant depression (TRD).
• The Option Agreement for olinciguat was terminated on October 23, 2025, as the parties could not agree on definitive license terms, and the company is now exploring new licensing opportunities for olinciguat.
• Cyclerion received an additional $0.5 million payment from Akebia Therapeutics in September 2025 as part of an amended license agreement for praliciguat, with potential for up to $558.5 million in future milestones and higher tiered royalties.
• Sold additional development materials to Akebia for $0.8 million during the three and nine months ended September 30, 2025.
• Tisento Therapeutics, in which Cyclerion holds a 10% equity interest, announced the first patient dosed in its Phase 2b PRIZM study for zagociguat in MELAS in January 2025 and received FDA Fast Track designation for zagociguat in MELAS in June 2025.
• The company successfully completed a private placement in March 2025, raising approximately $1.375 million gross proceeds, and initiated an 'at-the-market' (ATM) equity offering program, selling 604,166 shares for $1.8 million net proceeds from July to September 2025, and an additional 111,054 shares for $0.3 million net proceeds from October to November 2025.

Sentiment

Score: 4

Explanation: The sentiment is cautiously negative due to the explicit 'substantial doubt about the company's ability to continue as a going concern' and the ongoing need for capital. While there are positives like reduced net loss, increased revenue, successful capital raises, and a strategic pivot with a new license, the fundamental financial viability remains a significant concern, and the termination of the olinciguat option is a setback.

Positives

• Net loss for the nine months ended September 30, 2025, decreased by 24% to $2.729 million, compared to $3.587 million for the same period in 2024.
• Total revenues increased significantly by 441% to $1.049 million for the nine months ended September 30, 2025, primarily due to a purchase agreement with Akebia ($0.8 million) and option agreement revenue ($0.249 million).
• Net cash used in operating activities substantially decreased to $1.735 million for the nine months ended September 30, 2025, from $4.693 million in the prior year, indicating improved operational cash burn.
• Successfully raised $3.071 million in net cash from financing activities during the nine months ended September 30, 2025, through a private placement and an ATM program.
• Secured an exclusive worldwide license from MIT for a new product candidate targeting treatment-resistant depression (TRD), a high unmet medical need.
• Received a $0.5 million payment from Akebia and is eligible for substantial future development, regulatory, and commercialization milestone payments (up to $558.5 million) and higher-tiered sales-based royalties for praliciguat.
• Tisento Therapeutics, an investee, achieved significant clinical milestones including FDA Fast Track designation for zagociguat in MELAS and dosing the first patient in a Phase 2b study, potentially enhancing the value of Cyclerion's 10% equity interest.

Negatives

• Substantial doubt exists regarding the company's ability to continue as a going concern, with current cash expected to fund operations only into the second quarter of 2026.
• The Option Agreement for olinciguat was terminated due to an inability to agree on definitive license terms, indicating a setback in monetizing this legacy asset.
• Research and development expenses increased by 91% to $0.440 million for the nine months ended September 30, 2025, compared to $0.230 million in the prior year, driven by license fees, consulting, and outside service fees.
• General and administrative expenses increased by 16% to $4.744 million for the nine months ended September 30, 2025, from $4.094 million in the prior year, primarily due to professional consulting, outside service fees, and corporate legal fees.
• Interest income decreased by 51% to $0.089 million for the nine months ended September 30, 2025, compared to $0.180 million in the prior year, due to lower money market fund balances and reduced interest rates.
• The company continues to expect negative operating cash flows and will need additional funding to sustain operations for the foreseeable future.
• Management's plans to alleviate going concern doubt (reduced spending, additional capital) are considered 'less than probable' to be sufficient.

Risks

• Substantial doubt exists regarding the company's ability to continue as a going concern, necessitating additional capital in the near term.
• May not be successful in acquiring all necessary license and other rights, establishing clinical studies, obtaining regulatory approvals, and commercializing the new TRD product candidate.
• Inability to access capital, capabilities, and transactions necessary to advance the development of current and future product candidates.
• Significant uncertainty regarding future financial performance, potential revenues, expense levels, payments, cash flows, profitability, and tax obligations.
• Potential for substantial delays in developing, obtaining regulatory approval for, launching, and commercializing product candidates.
• Risk of being unable to maintain relationships with third parties, collaborators, and employees, or to execute strategic priorities.
• May fail to maintain its Nasdaq listing.
• Significant risks associated with the investment in Tisento Therapeutics Inc., including Tisento's ability to develop, obtain regulatory approval for, launch, and commercialize its product candidates.
• Uncertainty regarding any liquidity or monetizable value of the equity interest in Tisento, which faces all the risks of an early-stage pharmaceutical development company.
• Uncertainty as to whether any future development, regulatory, and commercialization milestones or royalty payments provided for in the agreement with Akebia Therapeutics, Inc. will be achieved.
• May be unsuccessful in out-licensing the olinciguat technology, potentially preventing commercialization or receipt of future royalty and milestone payments.
• Must maintain minimum royalty payments and meet certain milestones and other obligations to retain rights under the MIT License Agreement.
• Product candidates have not been approved for sale by regulatory agencies and may not meet safety and efficacy requirements; non-compliance with U.S. and non-U.S. regulatory requirements could negatively impact operating results.
• May be unable to obtain reimbursement from the U.S. government and third-party payors for potential future product candidates if commercialized.
• Inability to attract and retain employees or manage the impact of any loss of key employees could negatively affect financial condition and results of operations.
• Business may be negatively impacted if unable to obtain and maintain intellectual property protection for its own technology and licensed technology.
• Third parties may allege infringement of their intellectual property rights, leading to adverse outcomes.
• May fail to maintain effective internal controls over financial reporting.
• Impacted by trends and challenges in the markets affecting potential future product candidates.
• A determination that the company constitutes an investment company under the Investment Company Act of 1940 could have a material adverse effect.
• May be unable to compete with other companies developing or selling competitive products.
• A pandemic or natural disaster may disrupt business, including development activities, resulting in a material adverse effect on financial condition and results of operations.

Future Outlook

The company is focused on building a new pipeline with therapeutics for neuropsychiatric diseases, prioritizing an individualized therapy for treatment-resistant depression (TRD) following a license agreement with MIT. It plans to develop an integrated clinical, regulatory, and commercial strategy for TRD. Cyclerion expects to continue generating operating losses for the foreseeable future and will need additional funding to sustain operations beyond the second quarter of 2026. The company intends to leverage its legacy sGC stimulator assets to generate near-term revenues to support its strategic building plan in TRD and continues to evaluate other activities to enhance shareholder value, including collaborations, licenses, mergers, acquisitions, and targeted investments. The goal is to hire additional C-suite executives later this year.

Management Comments

• Our strategy for Cyclerion is to build a new pipeline with therapeutics to treat certain neuropsychiatric diseases.
• The team prioritized an individualized therapy for treatment resistant depression (TRD) as our foundational product candidate and we have entered into a license agreement with Massachusetts Institute of Technology (MIT) for the intellectual property associated with this product in September 2025.
• With the large unmet medical need in TRD, the clinical development stage of this asset, and the strong commercial opportunity, we believe that this potential product is well suited to be the foundation moving forward for Cyclerion.
• The program team is currently developing an Integrated clinical, regulatory and commercial strategy in TRD.
• In addition to significantly reducing operating expenses and the potential to obtain revenues from our legacy soluble guanylate cyclase (sGC) stimulator clinical assets, we intend to raise funds to support the execution of the product plans in TRD.
• We continue to build our infrastructure, and Regina Graul, Ph.D. was promoted to Chief Executive Officer (CEO) and Director to our Board in August of 2024 after she was hired as President in late 2023.
• Dr. Graul has significant experience in research and development, product search and evaluation and has extensive knowledge growing and leading integrated high-functioning teams.
• We also hired Rhonda Chicko, an independent contractor, as our Chief Financial Officer in 2024, who has extensive experience working with early and later-stage drug development companies.
• To limit our operating expenses, we have used consultants rather than hiring additional full-time employees; Dr. Graul is the only current employee to date and we currently rely on a team of specialist consultants to assist us in other areas of our operations.
• Our goal is to hire additional C-suite executives later this year.
• Management has concluded the likelihood that its plan to successfully obtain sufficient funding, or adequately reduce expenditures, while reasonably possible, is less than probable.

Industry Context

Cyclerion's strategic pivot from sGC stimulators to neuropsychiatric diseases, particularly treatment-resistant depression (TRD), aligns with a broader industry trend of addressing areas with high unmet medical needs. The reliance on out-licensing legacy assets and in-licensing new candidates is a common strategy for smaller biopharmaceutical companies to manage R&D costs and leverage external innovation. The success of Tisento's zagociguat in MELAS, including FDA Fast Track designation, highlights the increasing focus and regulatory support for rare disease indications, which can offer clearer development pathways and market opportunities. The company's lean operational model, relying heavily on consultants, is a capital-preservation tactic often employed by early-stage biotechs facing significant funding challenges.

Comparison to Industry Standards

• Cyclerion's 'going concern' warning is a common challenge for early-stage biotechnology companies, which typically operate at a loss for extended periods while developing product candidates. Many comparable small-cap biotechs frequently raise capital through equity offerings to fund operations.
• The strategy of out-licensing non-core assets (like praliciguat and olinciguat) and in-licensing new opportunities (like the MIT TRD technology) is a standard practice in the biotech industry to optimize portfolio value and manage R&D pipeline risks, similar to how companies like Xencor or Ligand Pharmaceuticals operate with their diverse licensing models.
• The FDA's Fast Track designation for Tisento's zagociguat in MELAS is a positive indicator, comparable to similar designations received by other rare disease drug developers, such as Sarepta Therapeutics for Duchenne muscular dystrophy treatments, which can accelerate development and regulatory review.
• The company's reliance on a single employee (CEO) and a team of specialist consultants for operations is an extremely lean model, more aggressive than many small biotechs which typically have a larger core management team, reflecting significant efforts to minimize operating expenses amidst financial constraints.

Management Changes

Legal Proceedings

• The company is not a party to any material legal proceedings at this time.

Stakeholder Impact

• **Shareholders**: Face significant dilution risk from ongoing equity capital raises (private placement, ATM program) and substantial uncertainty regarding the company's long-term viability due to the 'going concern' warning. The strategic pivot to TRD and potential milestones from Akebia offer future upside, but the termination of the olinciguat option is a negative.
• **Employees**: The company currently has only one employee (CEO) and relies on consultants, indicating a very lean structure. Future hiring of C-suite executives is planned, which could expand opportunities.
• **Customers/Patients**: The new focus on treatment-resistant depression (TRD) could eventually lead to new therapeutic options for patients with high unmet medical needs. The progress of Tisento's zagociguat in MELAS also offers hope for patients with that rare mitochondrial disease.
• **Creditors**: The 'going concern' warning and reliance on future capital raises pose a higher risk for creditors, as the company's ability to meet its obligations is uncertain without further funding.
• **Partners (Akebia, MIT)**: Akebia continues its development of praliciguat, with Cyclerion receiving payments and potential milestones. The new license agreement with MIT establishes a new partnership for TRD development. The termination of the olinciguat option means a potential partner for that asset was not secured.

Next Steps

• Develop an integrated clinical, regulatory, and commercial strategy for the new individualized therapy for treatment-resistant depression (TRD).
• Explore potential license opportunities for olinciguat following the termination of the previous Option Agreement.
• Raise additional capital to sustain operations beyond the second quarter of 2026.
• Continue to evaluate other activities aimed at enhancing shareholder value, including collaborations, licenses, mergers, acquisitions, and/or other targeted investments.
• Hire additional C-suite executives later this year to build out the management infrastructure.

Key Dates

Recommendation

The company's explicit 'going concern' warning is a critical red flag that typically warrants extreme caution or a 'sell' recommendation for new investors. However, the filing also presents several mitigating factors: a significant reduction in net loss and operating cash burn, successful capital raises through a private placement and an ATM program, and a strategic pivot to a high-potential area (TRD) with a new MIT license. The ongoing revenue from Akebia and the positive clinical progress of Tisento's asset (in which Cyclerion holds an equity stake) provide some upside potential. For existing investors, the current situation suggests a 'hold' as the company navigates its strategic shift and attempts to secure long-term funding. The successful capital raises indicate some market confidence, but the fundamental viability remains highly speculative. New investors should exercise extreme caution and likely 'avoid' until the going concern issue is definitively resolved and the TRD program shows more concrete progress.

Keywords

Biotechnology, Neuropsychiatric Disorders, Treatment Resistant Depression, TRD, Drug Development, SEC Filing, 10-Q, Pharmaceuticals, Licensing Agreement, Capital Raise, Going Concern, Clinical Trials, MELAS, sGC Stimulators, Praliciguat, Olinciguat, Zagociguat